

Antiviral Activity of Lenacapavir Against HIV-2 Isolates

Robert Smith,^{1*} Dana Raugi,² Robbie Nixon,¹ Moussa Seydi,² Nicolas Margot,³ Christian Callebaut,³ Geoffrey S. Gottlieb^{1,4}

¹Center for Emerging and Re-Emerging Infectious Diseases, University of Washington, Seattle, WA; ²Service des Maladies Infectieuses et Tropicales, CHNU de Fann, Dakar, Senega; ³Gilead Sciences, Inc., Foster City, CA; ⁴University of Washington, Seattle, WA

*Presenting author.

Introduction

- Lenacapavir (LEN) is a first-in-class, multistage inhibitor of HIV-1 capsid function in clinical development that was recently approved in Canada, the European Union, and the US for use in adults with multidrug-resistant HIV-1 infection¹⁻³
- LEN is highly potent against HIV-1 in vitro and maintains wild-type activity across HIV-1 isolates with resistance to all existing drug classes^{2,4}
- In clinical trials, LEN has shown high levels of efficacy in people with HIV-1 who are treatment-naïve or -experienced⁵⁻⁷; however, a comprehensive characterization of the antiviral activity of LEN against HIV-2 is lacking
- HIV-2 is endemic in West Africa and is found in other regions with socioeconomic ties to West African countries
 - HIV-2 is intrinsically resistant to many antiretroviral (ARV) drugs used for HIV-1 treatment
 - High rates of multiclass drug resistance have been reported in people living with HIV-2 (PLWH2) who have received ARV therapy; many such people have few fully active treatment options⁸⁻¹⁰
- The availability of a new, HIV-2-active ARV class could provide a much-needed option for second-line or salvage therapy and potentially improve ARV therapy outcomes in PLWH2


Objective

- To study the activity of LEN against a panel of HIV-2 isolates with or without resistance to existing drug classes

Methods


- The activity of LEN against HIV-1 and -2 isolates from ARV-naïve individuals was directly compared in 2 different assays: single-cycle infections of HeLa-CD4-CCR5-LTR-β-galactosidase (MAGIC-5A) indicator cells and multicycle infections of an immortalized T-cell line (CEM-NKR-CCR5-Luc)¹¹
- Drug-resistant HIV-2 variants with mutations in reverse transcriptase (RT) and integrase (IN) were tested for resistance to LEN in the single-cycle assay
- Simian immunodeficiency virus of macaques (SIV_{mac}) 251 was tested for LEN susceptibility in both single- and multicycle assays
- Sooty mangabey SIV (SIV_{sm}) E660, SIV_{mac} 239, and African green monkey SIV (SIV_{agm}) sab2 were also tested in the single-cycle assay

Virus Production and Titration




FFU = focus-forming units; NIH HRP = National Institutes of Health HIV Research Program; PBMC = peripheral blood mononuclear cells; TCID₅₀ = 50% tissue culture infectious dose.

Single-Cycle Drug Susceptibility Assays



Multicycle Drug Susceptibility Assays



Results

Susceptibility of HIV-1, HIV-2, and SIV Isolates to LEN: Single-Cycle Assay

Virus	Isolate	Group/Subtype	IC ₅₀ , nM ^a	No. of Assays
HIV-1	92UG029	M/A	0.19 ± 0.067	3
	NL4-3	M/B	0.15 ± 0.067	10
	89.6	M/B	0.22 ± 0.079	3
	LAI	M/B	0.14 ± 0.036	3
	MJ4	M/C	0.31 ± 0.18	4
	92UG001	M/D	0.23 ± 0.066	3
	94UG114.1.6	M/D	0.20 ± 0.064	3
	93BR020	M/F	0.31 ± 0.15	3
	MVP5180-91	O	0.19 ± 0.080	3
	BCF01	O	0.14 ± 0.031	3
HIV-2	ROD9	A	2.3 ± 0.98	5
	ST	A	1.6 ± 0.33	3
	7924A	A	2.2 ± 0.85	3
	MVP15132	A	2.8 ± 0.93	3
	60415K	A	2.7 ± 0.33	3
	CBL-20	A	2.4 ± 0.24	3
	CBL-23	A	1.7 ± 0.80	3
	CDC77618	A	2.6 ± 0.40	3
	EHO	B	2.5 ± 0.42	3
	CDC310072	B	2.5 ± 0.44	3
SIV	7312A	CRF01_AB	1.1 ± 0.10	3
	sm E660	-	0.85 ± 0.11	3
	mac239 SpX	-	0.81 ± 0.37	3
	mac251	-	1.1 ± 0.077	3
	agm sab2	-	0.61 ± 0.14	3

^aSingle-cycle infections of MAGIC-5A cells. IC₅₀ = half-maximal inhibitory concentration.

- In the single-cycle assay, LEN inhibited HIV-1 with a mean IC₅₀ of 210 pM (range 140-310 [n = 10 isolates])
- In comparison, the mean IC₅₀ for HIV-2 was 2.3 nM (range 1.1-3.2 [n = 12 isolates]), indicating an average 11-fold decrease in the activity of LEN against HIV-2 vs -1
- SIV isolates from SIV_{sm} as well as SIV_{agm} sab2, showed susceptibilities to LEN that were similar to HIV-2


Susceptibility of HIV-1, HIV-2, and SIV Isolates to LEN: Multicycle Assay

Virus	Isolate	Group/Subtype	IC ₅₀ , nM ^a	No. of Assays
HIV-1	92UG029	M/A	0.20 ± 0.068	2
	Q23-17	M/A	0.12 ± 0.038	2
	NL4-3	M/B	0.12 ± 0.071	2
	LAI	M/B	0.12 ± 0.037	2
	93BR020	M/F	0.17 ± 0.094	3
	BCF01	O	0.074 ± 0.0051	2
	ROD9	A	3.1 ± 0.36	2
	ST	A	1.3 ± 0.32	2
	MVP15132	A	1.2	1
	60415K	A	2.6 ± 0.87	2
HIV-2	CDC77618	A	1.2 ± 0.018	2
	CDC310072	B	2.8 ± 1.9	2
	CDC310319	B	3.4 ± 1.9	3
	7312A	CRF01_AB	1.1 ± 0.16	2
	SIV mac251	-	1.3 ± 0.57	2

^aMulticycle infections of CEM-NKR-CCR5-Luc cells.

- In the multicycle assay, a comparable difference in LEN activity between HIV-1 and -2 was noted, with mean IC₅₀ values of 130 pM for HIV-1 (range 74-200 [n = 6 isolates]) and 2.1 nM for HIV-2 (range 1.1-3.4 [n = 8 isolates])

Representative LEN Dose-Response Curves



Data are from single-cycle assay; data points indicate amounts of β-galactosidase activity produced in LEN-treated cultures relative to solvent-only (ie, no-drug) control cultures; each point is mean of 2 cultures that were maintained in parallel; IC₅₀ and R² values were calculated using 4-factor regression model in Prism v6.0h (GraphPad Software, Boston, MA); error bars indicate standard deviations (SDs).


Activity of LEN Against Drug-Resistant HIV-2 Mutants

Virus	Mutated Clone	Region	Mutation	Fold IC ₅₀ , nM ^a	Difference ^b
HIV-2	pROD9	None	None	1.3 ± 0.23	-
HIV-2	pROD9	RT	K65R+Q151M+M184V	1.0 ± 0.015	0.79
		RT ^c	K65R+N69S+V111H+Q151M+M184V	0.96 ± 0.0053	0.73
		IN	I84V+Q91R+T97A+Y143C	1.2 ± 0.048	0.93
		IN	G140S+Q148H	1.2 ± 0.17	1
		IN	R263K	1.6 ± 0.24	1.2
			231ins SREGK ^d	1.2 ± 0.48	0.92
HIV-1	pNL4-3	None	None	0.10 ± 0.0056	0.08

^aSingle-cycle infections of MAGIC-5A cells; IC₅₀ values are means ± SDs of 2 independent determinations; ^bRelative to IC₅₀ for wild-type HIV-2_{ROD9}; ^cThis clone contains patient-derived RT insert; additional amino acid differences relative to pROD9 RT were as follows: K30R, K64R, P126Q, V135T, V167I, K176P, I180L, F214L, H228Q, I251V, L270I, and K277R; ^dinsertion of 5 amino acids (serine-arginine-glutamic acid-glycine-lysine) at codon 231 of IN.

- Presence of drug resistance mutations in HIV-2 RT or IN had no effect on LEN activity (fold-change in LEN IC₅₀: 0.73-1.2 relative to wild-type HIV-2_{ROD9})

Summary: Activity of LEN Against HIV-1 and HIV-2 Isolates



Symbols indicate mean IC₅₀ values observed for individual isolates of HIV-1 and -2; P values calculated via analysis of variance with Tukey's post-test.

Conclusions

- In this study, LEN was active against HIV-2 isolates with low-nanomolar activity
- LEN potency against HIV-2 was reduced 11- to 16-fold in comparison to HIV-1 regardless of presence of drug resistance mutations in HIV-2 RT or IN
- As a result of this difference in potency, treating PLWH2 with a LEN-based regimen could require careful monitoring to assess virologic responsiveness
- These data provide information on the potential clinical utility of LEN in PLWH2 for whom treatment options are limited

References: 1. Bester S, et al. Science 2020;370:360-4; 2. Link J, et al. Nature 2020;584:614-8; 3. Paik L. Drugs 2022;82:1499-504; 4. Margot N, et al. Antimicrob Agents Chemother 2021;65:e02057-20; 5. Margot N, et al. J Antimicrob Chemother 2022;77:989-95; 6. Margot N, et al. J Infect Dis 2022;226:1985-91; 7. Segal-Maurer S, et al. N Engl J Med 2022;386:1793-803; 8. Berzow D, et al. Clin Infect Dis 2021;72:503-9; 9. Gottlieb G, et al. Lancet HIV 2018;5:e390-9; 10. Visseaux B, et al. Infect Genet Evol 2016;46:233-40; 11. Smith RA, et al. J Infect Dis 2022;226:497-509.

Acknowledgments: This study was funded by grants to Dr Gottlieb from the National Institute of Allergy and Infectious Diseases at the NIH (R01 AI120765), and the University of Washington Center for AIDS Research (NIH-funded program P30 AI027757). These agencies had no role in the design of the study, data collection, or interpretation of the findings. LEN was kindly provided by Gilead Sciences, Inc. Editing and production assistance were provided by BioScience Communications, New York, NY, funded by Gilead. Disclosures: R Smith, D Raugi, R Nixon: nothing to disclose; M Seydi: grant funds and clinical support from Gilead, ANRS, GSK; N Margot, C Callebaut: employees and shareholders of Gilead; GS Gottlieb: research grants and support from Gilead, Abbott, Aleris, Bill & Melinda Gates Foundation, BMS, Cerus, Janssen, MSD, Roche, NIH, Theratechnologies/TaiMed, University of Washington, Viiv.